Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality

• Main Authors: Olender, Susan A., Walunas, Theresa L., Martinez, Esteban, Perez, Katherine K., Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G., De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M., Lye, David C., Gottlieb, Robert L., Haubrich, Richard H., Chokkalingam, Anand P., Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M., Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O., Bernardino, Jose I., Boffito, Marta
• 其他作者: Lee Kong Chian School of Medicine (LKCMedicine)
• 格式: Article
• 語言: English
• 出版: 2022
• 主題: Science::Medicine; Mortality; Remdesivir
• 在線閱讀: https://hdl.handle.net/10356/154077
• 機構: Nanyang Technological University

Background: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. Methods: This was the final day 28 compa...